Eos Management L.P. Makes New Investment in Charles River Laboratories International, Inc. $CRL

Eos Management L.P. purchased a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 4,206 shares of the medical research company’s stock, valued at approximately $839,000.

Other hedge funds also recently modified their holdings of the company. Tema Etfs LLC acquired a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $26,000. Rothschild Investment LLC grew its holdings in Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after acquiring an additional 84 shares during the period. Los Angeles Capital Management LLC bought a new stake in Charles River Laboratories International in the fourth quarter worth about $42,000. Sfam LLC bought a new position in shares of Charles River Laboratories International during the 4th quarter valued at about $43,000. Finally, Activest Wealth Management boosted its position in shares of Charles River Laboratories International by 10,900.0% during the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 218 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Price Performance

CRL stock opened at $185.17 on Friday. Charles River Laboratories International, Inc. has a one year low of $144.26 and a one year high of $228.88. The firm has a 50-day moving average of $174.82 and a two-hundred day moving average of $182.71. The firm has a market capitalization of $8.92 billion, a PE ratio of -49.25, a P/E/G ratio of 2.12 and a beta of 1.46. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The business had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm’s revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, analysts forecast that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on CRL. Evercore reiterated an “outperform” rating and issued a $220.00 target price on shares of Charles River Laboratories International in a report on Friday, May 8th. Weiss Ratings cut shares of Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Morgan Stanley upgraded shares of Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $185.00 to $220.00 in a research report on Wednesday. TD Cowen dropped their price target on Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Finally, Wall Street Zen downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has an average rating of “Moderate Buy” and a consensus price target of $211.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.